Volume 70, Issue 2, Pages (August 2016)

Slides:

Advertisements

Similar presentations

Volume 70, Issue 2, Pages (August 2016)

Advertisements

Volume 68, Issue 4, Pages (October 2015)

Volume 58, Issue 3, Pages (September 2010)

Volume 70, Issue 3, Pages (September 2016)

Volume 63, Issue 3, Pages (March 2013)

Volume 64, Issue 3, Pages (September 2013)

Volume 58, Issue 2, Pages (August 2010)

Volume 55, Issue 3, Pages (March 2009)

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Global Trends in Testicular Cancer Incidence and Mortality

Volume 57, Issue 1, Pages (January 2010)

Volume 59, Issue 3, Pages (March 2011)

Contemporary Management of the Painful Bladder: A Systematic Review

Volume 61, Issue 1, Pages (January 2012)

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 56, Issue 3, Pages (September 2009)

Volume 73, Issue 2, Pages (February 2018)

Volume 49, Issue 2, Pages (February 2006)

Volume 61, Issue 5, Pages (May 2012)

Volume 68, Issue 3, Pages (September 2015)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 2, Pages (February 2016)

Volume 70, Issue 4, Pages (October 2016)

Volume 74, Issue 2, Pages (August 2018)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Bladder Cancer: Management and Future Directions

Ashish M. Kamat, Sima Porten European Urology

Volume 73, Issue 5, Pages (May 2018)

Volume 51, Issue 5, Pages (May 2007)

Volume 70, Issue 5, Pages (November 2016)

Volume 71, Issue 2, Pages (February 2017)

Volume 63, Issue 4, Pages (April 2013)

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 66, Issue 2, Pages (August 2014)

Volume 71, Issue 6, Pages (June 2017)

What is New in Bladder Cancer Diagnosis and Management?

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 55, Issue 6, Pages (June 2009)

Volume 66, Issue 4, Pages (October 2014)

Volume 61, Issue 5, Pages (May 2012)

Volume 61, Issue 4, Pages (April 2012)

Volume 63, Issue 5, Pages (May 2013)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 55, Issue 3, Pages (March 2009)

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

Volume 71, Issue 6, Pages (June 2017)

Volume 61, Issue 6, Pages (June 2012)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 53, Issue 1, Pages (January 2008)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 68, Issue 4, Pages (October 2015)

Volume 50, Issue 3, Pages (September 2006)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations Raj Persad, Donald Lamm,

Volume 53, Issue 5, Pages (May 2008)

Bladder Cancer: Highlights from 2006

Volume 52, Issue 4, Pages (October 2007)

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Volume 52, Issue 1, Pages (July 2007)

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

Volume 70, Issue 2, Pages 341-347 (August 2016) Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon- α2a in Reducing Recurrence of Non–Muscle-invasive Bladder Carcinoma: FinnBladder- 6 Study Timo Marttila, Riikka Järvinen, Tapani Liukkonen, Erkki Rintala, Peter Boström, Marjo Seppänen, Teuvo Tammela, Pekka Hellström, Sirpa Aaltomaa, Markku Leskinen, Mika Raitanen, Eero Kaasinen European Urology Volume 70, Issue 2, Pages 341-347 (August 2016) DOI: 10.1016/j.eururo.2016.03.034 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Flowchart of the FinnBladder-6 study. A1=bacillus Calmette-Guérin 12 mo; A2=bacillus Calmette-Guérin 24 mo; B1=epirubicin and interferon 12 mo; B2=epirubicin and interferon 24 mo; BCG=bacillus Calmette-Guérin; C=cystoscopy and cytology every 3 mo; IFN=interferon; R=randomization; TURB=transurethral resection of the bladder; ↑↓=bladder instillation therapy. European Urology 2016 70, 341-347DOI: (10.1016/j.eururo.2016.03.034) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 The cumulative incidence curves of time to first recurrence in the pooled 1- and 2-yr maintenance bacillus Calmette-Guérin group and in the pooled 1- and 2-yr maintenance epirubicin plus interferon group. BCG=bacillus Calmette-Guérin; CI=confidence interval; EPI=epirubicin; HR=hazard ratio; IFN=interferon; N=number of patients; O=observed number of events. European Urology 2016 70, 341-347DOI: (10.1016/j.eururo.2016.03.034) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 3 The cumulative incidence curves of time to progression in the pooled 1- and 2-yr maintenance bacillus Calmette-Guérin group and in the pooled 1- and 2-yr maintenance epirubicin plus interferon group. BCG=bacillus Calmette-Guérin; CI=confidence interval; EPI=epirubicin; HR=hazard ratio; IFN=interferon; N=number of patients; O=observed number of events. European Urology 2016 70, 341-347DOI: (10.1016/j.eururo.2016.03.034) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 4 The cumulative incidence curves of disease-specific mortality and the Kaplan-Meier curves of overall survival in the pooled 1- and 2-yr maintenance bacillus Calmette-Guérin group and in the pooled 1- and 2-yr maintenance epirubicin plus interferon group. BCG=bacillus Calmette-Guérin; CI=confidence interval; EPI=epirubicin; HR=hazard ratio; IFN=interferon; N=number of patients; O=observed number of events. European Urology 2016 70, 341-347DOI: (10.1016/j.eururo.2016.03.034) Copyright © 2016 European Association of Urology Terms and Conditions